In a setback, Regeneron reports a mid-stage flop for next-gen Eylea combo
Regeneron has run into a rare clinical setback. The big biotech reports that one of its next-gen Eylea combos flopped in a Phase II study, falling short on the primary as well as secondary endpoints. And analysts quickly started to assess the potential implications for a rival combo now in Phase III at Ophthotech.
Regeneron added the anti-PDGF antibody rinucumab to its blockbuster drug for age-related macular degeneration. After 12 weeks of therapy the patients in the combo group demonstrated a 5.8-letter improvement in a commonly used eye test. But that compared poorly against the 7.5-letter improvement for Eylea alone.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
